Mochida Pharmaceutical Co., Ltd. (4534) AI Stock Analysis

• Market Cap: €109.06B
• Dividend Yield: 2.49%
• Average Volume (3M): 21.15K
• Price to Earnings (P/E): 18.9
• Beta (1Y): 0.53
• Revenue Growth: 2.74%
• EPS Growth: 36.86%
• Country: JP
• Employees: 1,522
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 53.43
• Shares Outstanding: 36,390,000
• 10 Day Avg. Volume: 18,600
• 30 Day Avg. Volume: 21,146
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €3,459.46
• Price Target Upside: 7.60% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 69 Neutral
• Price Target: ¥3,460.00 ▲(7.62% Upside)

Mochida Pharmaceutical's overall stock score reflects its strong financial stability and profitability, offset by declining revenue growth and volatile cash flow trends. The technical indicators suggest a neutral to slightly positive outlook, while the valuation is fair with a reasonable dividend yield. The absence of earnings call data and corporate events limits additional insights.

Mochida Pharmaceutical Co., Ltd. Business Overview & Revenue Model

Company Description

Mochida Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company that focuses on the research, development, manufacturing, and marketing of prescription drugs, particularly in the fields of neurology, psychiatry, and urology. Established in 1949, Mochida has a diverse portfolio of products that include innovative therapeutic agents, generics, and over-the-counter medications. The company is dedicated to improving patient care through advanced medical solutions and has a strong presence in both domestic and international markets.

How the Company Makes Money

Mochida Pharmaceutical generates revenue primarily through the sale of its pharmaceutical products, which include proprietary drugs and generic medications. The company benefits from a diversified revenue model that includes sales from both domestic and international markets. Key revenue streams come from the marketing of its proprietary drugs, which are developed through extensive research and clinical trials, as well as partnerships with other pharmaceutical companies for co-development and distribution. Additionally, Mochida engages in licensing agreements that allow it to earn royalties on its patented products. The company's consistent focus on innovation, coupled with strategic collaborations and a robust product pipeline, significantly contributes to its financial performance.

Mochida Pharmaceutical Co., Ltd. Financial Statement Overview

Summary

Mochida Pharmaceutical Co., Ltd. exhibits a stable financial standing with strengths in its balance sheet, characterized by zero debt and a high equity ratio, ensuring financial stability and low risk. The income statement reflects moderate profitability and revenue growth, while the cash flow statement raises concerns with negative free cash flow and undefined cash flow ratios, which could affect liquidity if sustained. Overall, the company is well-positioned but should focus on enhancing cash flow efficiencies.

Income Statement

Mochida Pharmaceutical has shown a resilient performance in its income statement. The TTM gross profit margin stands at 50.44%, indicative of strong cost control. However, the net profit margin of 5.42% highlights some challenges in converting revenue into net income. Revenue growth has been relatively flat with a slight TTM increase of 2.44% from the previous year. The EBIT margin is 6.88%, which is modest, while the EBITDA margin of 3.28% suggests limited operating leverage.

Balance Sheet

The company's balance sheet is robust, with zero total debt and a strong equity base. The debt-to-equity ratio is effectively 0, indicating no reliance on debt. The return on equity (ROE) for the TTM is 4.38%, which is moderate but stable. The equity ratio stands at 78.50%, showcasing a solid asset financing structure with a high proportion of equity.

Cash Flow

Mochida Pharmaceutical's cash flow statement indicates some concerns. While operating cash flow has been positive historically, the TTM data shows zero, which may be due to reporting timing or other factors. The free cash flow for the last annual period was significantly negative due to high capital expenditures. The free cash flow to net income ratio is undefined due to zero free cash flow, posing a risk to cash-based operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	105.16B	105.16B	102.89B	103.26B	110.18B	103.00B
Gross Profit	53.79B	53.79B	52.07B	55.12B	59.55B	54.79B
EBITDA	10.79B	11.00B	8.97B	11.71B	17.28B	14.75B
Net Income	5.68B	5.68B	4.55B	6.65B	10.57B	8.59B
Balance Sheet
Total Assets	160.12B	160.12B	158.80B	158.83B	163.14B	161.79B
Cash, Cash Equivalents and Short-Term Investments	51.15B	51.15B	46.79B	60.51B	61.91B	63.49B
Total Debt	342.00M	342.00M	369.00M	190.00M	0.00	0.00
Total Liabilities	29.43B	29.43B	30.83B	32.06B	34.50B	34.82B
Stockholders Equity	130.69B	130.69B	127.97B	126.77B	128.64B	126.97B
Cash Flow
Free Cash Flow	0.00	7.19B	-9.78B	5.13B	4.36B	7.11B
Operating Cash Flow	0.00	9.35B	-7.48B	7.30B	7.46B	9.20B
Investing Cash Flow	0.00	17.36B	74.00M	-2.95B	-2.01B	-880.00M
Financing Cash Flow	0.00	-2.87B	-6.39B	-6.88B	-5.96B	-5.11B

Mochida Pharmaceutical Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3215.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4534, the sentiment is Positive. The current price of 3215 is above the 20-day moving average (MA) of 3195.25, above the 50-day MA of 3120.50, and above the 200-day MA of 3154.94, indicating a bullish trend. The MACD of 28.41 indicates Positive momentum. The RSI at 52.42 is Neutral, neither overbought nor oversold. The STOCH value of 33.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4534.

Mochida Pharmaceutical Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4521	80 Outperform	139.03B	11.62	9.14%	2.98%	31.19%	72.28%
4553	72 Outperform	146.36B	9.20	11.06%	2.35%	11.11%	-5.42%
4547	71 Outperform	181.56B	15.23	5.72%	2.02%	15.40%	7.73%
4534	69 Neutral	€109.06B	18.86	4.88%	2.49%	2.74%	36.86%
4569	69 Neutral	79.49B	8.53	6.67%	3.44%	9.83%	86.18%
4886	68 Neutral	63.50B	13.36	7.81%	2.10%	6.23%	-31.45%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Mochida Pharmaceutical Co., Ltd. Corporate Events

Mochida Pharmaceutical Reports Robust Profit Growth for 2024

Mochida Pharmaceutical Co., Ltd. announced its consolidated financial results for the nine months ending December 31, 2024, showing a significant improvement in operating and ordinary profit compared to the previous year. The company reported a 3.2% increase in net sales and marked a substantial rise in profits, indicating a strong performance in its operations despite a drop in comprehensive income.